Prime Performance.
Today and Tomorrow.
ACURATE Prime™ is a self-expanding, supra-annular valve designed to optimise outcomes in transcatheter aortic valve implantation (TAVI) procedures. With proven ease of use, predictable performance, while preserving future coronary access, it supports precision at every step of TAVI.
Designed to support precision during every TAVI procedure, ACURATE Prime features a split-level design, top-down deployment, and predictable commissural alignment.
Whether for a first-time TAVI procedure or a complex TAVI-in-TAVI case, its open-cell frame design and supra-annular leaflets provide consistent hemodynamic performance and post-procedure access flexibility.
Elevate your TAVI experience with ACURATE Prime.
ACURATE Prime™ has a broad size matrix to accommodate a wide range of annulus diameters, enabling treatment in both standard and complex TAVI procedures.
| Valve size | 23 mm | 25 mm | 27 mm | 29 mm |
|---|---|---|---|---|
| Aortic annulus diameter* | 20.5 mm - 23 mm | 22.5 mm - 25 mm | 24.5 mm - 27 mm | 26.5 mm - 29 mm |
| Aortic annulus perimeter | 64 mm - 72 mm | 71 mm - 79 mm | 77 mm - 85 mm | 83 mm - 91 mm |
The Early ACURATE Prime Registry is the first real-world study evaluating the ACURATE PrimeTM Aortic Valve System.
This prospective, multicenter registry enrolled N=517 patients to assess the 30-day performance of the ACURATE Prime Aortic Valve System. The results demonstrated an excellent safety and efficacy profile in a real-world clinical setting.
Below are the key 30-day outcomes as presented by Dr. Andreas Rück at EuroPCR 2025:
Early ACURATE Prime Registry:
30 day results
*CT-based measurement: Perimeter-derived annulus.
1. Bieliauskas G, Wong I, Bajoras V, et al. Patient-Specific Implantation Technique to Obtain Neo-Commissural Alignment With Self-Expanding Transcatheter Aortic Valves. JACC Cardiovasc Interv. 2021 October 11;14(19):2097–2108.
2. Kim WK, Tamburino C, Möllmann H, et al. Clinical outcomes of the ACURATE neo2 transcatheter heart valve: a prospective, multicenter, observational, post-market surveillance study. EuroIntervention. 2023;19(1):83-92
3. Rück A, Kim WK, Abdel-Wahab M, et al. The Early neo2 Registry: Transcatheter Aortic Valve Implantation with ACURATE neo2 in a European Population. J Am Heart Assoc. 2023 Aug;12(15):e029464
4. Barbanti M, Costa G, Picci A, et al. Coronary Cannulation After Transcatheter Aortic Valve Replacement: The RE-ACCESS Study. JACC Cardiovasc Interv. 2020 Nov 9;13(21):2542-2555.
5. Möllmann et al. Five-year outcomes of transcatheter aortic valve implantation with the ACURATE neo2 valve system, EuroIntervention 2024, e951-e953, 10.4244/EIJ-D-23-00852
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. 2024 Copyright © Boston Scientific Corporation or its affiliates. All rights reserved.
CE 0344
